Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

Dr. Reddy's Laboratories Ltd. closed 17.18% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...

Besides generics, Dr. Reddy’s has committed a lot of resources to develop its biosimilars as well as new chemical entity business. Biosimilars have been seen as a growth engine for large, capable ...

Uncertainties around US tariffs and the end of the limited competition period for generic Revlimid in the US will loom in ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.

Shares of Bajaj Finance, Bajaj Finserv, Trent, Ambuja, BPCL, and NTPC Green are likely to be in the focus as these companies ...

Hyderabad gastroenterologist D. Nageshwar Reddy awarded Padma Vibhushan for medical contributions by President Murmu.

Within three years, Apollo became profitable. Dr. Reddy then established hospitals in cities like Ahmedabad, Bilaspur, Mysore ...